Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
- Revenue in USD (TTM)0.00
- Net income in USD-60.93m
- Incorporated1987
- Employees16.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Codiak BioSciences Inc | 22.45m | -34.88m | 60.51m | 102.00 | -- | 1.25 | -- | 2.70 | -1.57 | -1.57 | 1.01 | 2.15 | 0.1314 | -- | -- | 220,078.40 | -20.42 | -- | -22.18 | -- | -- | -- | -155.37 | -- | -- | -26.33 | 0.3453 | -- | 686.79 | -- | 63.75 | -- | -- | -- |
| Akebia Therapeutics Inc | 222.97m | -275.68m | 60.57m | 426.00 | -- | 2.32 | -- | 0.2716 | -1.61 | -1.61 | 1.29 | 0.1424 | 0.3831 | 2.79 | 4.47 | 523,410.80 | -47.37 | -36.48 | -74.76 | -52.84 | 47.27 | 68.21 | -123.64 | -94.35 | 1.04 | -12.82 | 0.7893 | -- | -27.68 | 168.34 | 26.24 | -- | -53.32 | -- |
| Natural Alternatives International, Inc. | 162.83m | 10.57m | 60.83m | 220.00 | 5.85 | 0.7145 | 4.08 | 0.3736 | 1.69 | 1.69 | 26.09 | 13.84 | 1.28 | 4.03 | 9.69 | 740,140.90 | 8.32 | 6.61 | 10.25 | 8.12 | 18.51 | 18.17 | 6.49 | 4.49 | 1.70 | 76.56 | 0.1039 | -- | 50.17 | 9.35 | 754.59 | 2.44 | -13.33 | -- |
| DSwiss Inc | 2.12m | 133.79k | 61.62m | 9.00 | 458.15 | 594.58 | 332.29 | 29.11 | 0.0007 | 0.0007 | 0.0102 | 0.0005 | 4.61 | 62.58 | 20.89 | 235,156.70 | 33.00 | -31.31 | 198.66 | -85.67 | 23.51 | 28.77 | 7.16 | -19.45 | 1.02 | 37.39 | 0.395 | -- | 45.33 | 70.19 | 1,550.39 | -- | 2.46 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -13.48m | 61.88m | 14.00 | -- | 1.52 | -- | -- | -0.6107 | -0.6107 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -40.49 | -57.44 | -42.15 | -62.64 | -- | -- | -- | -9,305.40 | -- | -- | 0.0004 | -- | -- | -- | -10.58 | -- | 26.14 | -- |
| SCYNEXIS Inc | 1.80m | -33.64m | 61.90m | 56.00 | -- | 1.43 | -- | 34.39 | -1.21 | -1.21 | 0.0641 | 1.33 | 0.017 | -- | 1.37 | 32,142.86 | -31.79 | -51.44 | -38.72 | -62.60 | 77.17 | -- | -1,868.94 | -1,299.38 | 7.78 | -- | 0.5336 | -- | -- | 119.73 | 40.44 | -- | 112.58 | -- |
| Seelos Therapeutics Inc | 0.00 | -60.93m | 61.97m | 16.00 | -- | 1.35 | -- | -- | -0.6016 | -0.6016 | 0.00 | 0.4322 | 0.00 | -- | -- | 0.00 | -108.75 | -190.52 | -137.55 | -336.13 | -- | -- | -- | -40,434.13 | -- | -68.36 | 0.2957 | -- | -- | -- | -245.78 | -- | -- | -- |
| Adamis Pharmaceuticals Corp | 1.97m | -30.93m | 62.05m | 15.00 | -- | 3.90 | -- | 31.50 | -0.2011 | -0.2683 | 0.0134 | 0.1062 | 0.0354 | 5.01 | 1.45 | 131,339.30 | -55.62 | -67.59 | -81.06 | -91.72 | -229.45 | 16.94 | -1,569.87 | -277.05 | 2.04 | -- | 0.1042 | -- | -20.45 | -19.35 | 3.48 | -- | 58.81 | -- |
| Achieve Life Sciences Inc | 0.00 | -32.73m | 62.45m | 16.00 | -- | 2.85 | -- | -- | -3.79 | -3.79 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -88.12 | -68.48 | -98.05 | -79.40 | -- | -- | -- | -- | -- | -94.00 | 0.4145 | -- | -- | -- | -125.06 | -- | -- | -- |
| BIOQUAL, Inc. | 64.42m | 5.50m | 62.61m | 108.00 | 11.39 | 1.75 | 8.73 | 0.9719 | 6.14 | 6.14 | 72.02 | 40.01 | 1.15 | -- | 2.74 | -- | 9.79 | 12.77 | 11.44 | 14.84 | 22.21 | 23.01 | 8.53 | 9.65 | -- | -- | 0.00 | 14.79 | 24.42 | 11.78 | 49.54 | 17.06 | 55.63 | 25.74 |
| ImmuCell Corporation | 21.14m | 1.10m | 63.10m | 47.00 | 57.77 | 1.89 | 17.72 | 2.99 | 0.1411 | 0.1411 | 2.72 | 4.31 | 0.4897 | 3.95 | 8.38 | 352,258.30 | 2.55 | -2.74 | 2.68 | -2.93 | 48.06 | 46.86 | 5.20 | -7.11 | 6.32 | 4.97 | 0.2466 | -- | 25.43 | 15.06 | 92.34 | -- | -6.17 | -- |
| Bolt Biotherapeutics Inc | 2.07m | -97.82m | 63.33m | 91.00 | -- | 0.2773 | -- | 30.55 | -2.64 | -2.64 | 0.0559 | 6.10 | 0.0068 | -- | -- | 22,780.22 | -32.21 | -- | -33.96 | -- | -- | -- | -4,718.52 | -- | -- | -- | 0.00 | -- | 445.45 | -- | -62.35 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 33.49m | -31.37m | 63.46m | 168.00 | -- | 0.8463 | -- | 1.89 | -0.2252 | -0.2252 | 0.2404 | 0.5511 | 0.2413 | 4.16 | 4.21 | 199,369.00 | -22.01 | -35.38 | -29.39 | -43.33 | 58.33 | -- | -91.23 | -337.70 | 3.53 | -- | 0.00 | -- | 99.25 | -- | 24.09 | -- | 133.52 | -- |
Data as of May 25 2022. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
28.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2022 | 5.87m | 5.56% |
| The Vanguard Group, Inc.as of 31 Mar 2022 | 5.46m | 5.17% |
| Tontine Associates LLCas of 31 Mar 2022 | 4.93m | 4.67% |
| Woodline Partners LPas of 31 Mar 2022 | 2.80m | 2.66% |
| Group One Trading LPas of 31 Mar 2022 | 2.24m | 2.12% |
| Horizons ETFs Management (Canada), Inc.as of 31 Mar 2022 | 1.93m | 1.83% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 1.75m | 1.65% |
| Renaissance Technologies LLCas of 31 Mar 2022 | 1.72m | 1.63% |
| Geode Capital Management LLCas of 31 Mar 2022 | 1.62m | 1.53% |
| Uniplan Investment Counsel, Inc.as of 31 Mar 2022 | 1.56m | 1.48% |
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
